Brief: Synaptogenix Completes Patient Enrollment In NIH Sponsored Phase 2B Alzheimer's Disease Trial
19/04/2022 14:21
April 19 (Reuters) - Synaptogenix Inc SNPX.O :
* SYNAPTOGENIX COMPLETES PATIENT ENROLLMENT IN NIH SPONSORED
PHASE
2B ALZHEIMER'S DISEASE TRIAL
Source text for Eikon: ID:nPn5rR44la
Further company coverage: SNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TAO Synergies
See all newsBrief: Tao Synergies Announces Preliminary Inclusion In Russell Microcap Index For 2026
Brief: Tao Synergies Inc - Increases Tao Holdings to 54,058 Tokens
Brief: Tao Synergies Accelerates Decentralized AI Treasury Strategy With 42,111 Bittensor Tokens
Brief: Synaptogenix Renamed TAO Synergies, New Ticker "TAOX" for AI-Focused Crypto Strategy
Brief: Synaptogenix Announces Initial TAO Acquisition Under Crypto Treasury Strategy